Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Principal investigator hypothesize that TRAIL D5 antibody DS-8273a administered in combination with nivolumab will be well tolerated and that the addition of DS-8273a will augment the clinical efficacy of nivolumab.